|
RESEARCH AND LICENSE AGREEMENT (Details Textual) (USD $)
In Thousands, except Share data, unless otherwise specified
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
Feb. 28, 2011
|
Jan. 31, 2011
|
Dec. 24, 2009
|
Mar. 31, 2013
|
Dec. 31, 2009
|
| Research License Agreement Expenses Paid |
|
|
$ 400 |
|
$ 400 |
| Research License Payments Made As Per Settlement Agreement |
5 |
|
|
|
|
| Shares Granted As Per Research And License Agreement |
|
|
|
|
1,120,000 |
| Selling Of Shares Term |
|
|
|
|
185 days |
| Number Of Shares Sold By Purchaser As Permitted By Settlement Agreement |
|
167,530 |
|
|
|
| Proceeds From Shares Issued |
|
|
|
|
Company would pay to Ramot the difference between the proceeds that Ramot has received from sales of the shares up to such date together with the September Payment (if any) that has been transferred to Ramot up to such date, and $240. |
| Proceeds From Shares Sold By Purchaser As Permitted By Settlement Agreement |
|
35 |
|
|
|
| Value Of Shares Granted To Purchaser As Per Research and License Agreement |
|
235 |
|
|
|
| Obligation Amount To Fund Extended Research Period |
|
|
1,140 |
|
1,140 |
| Research and Development Expenses Reversed |
|
|
|
|
760 |
| Stock Based Compensation Related To Shares Granted Under Research License Agreement |
|
|
|
|
51 |
| Research License Interest Rate |
|
|
|
|
32 |
| Percentage Of Royalty Covered By Valid Claim Or Orphan Drug Status |
|
|
|
5.00% |
|
| Percentage Of Royalty Not Covered By Valid Claim Or Orphan Drug Status |
|
|
|
3.00% |
|
| Percentage Of Royalty Expiration Not Covered By Valid Claim Or Orphan Drug Status |
|
|
|
15 years |
|
|
Initial Research Period [Member]
|
|
|
|
|
|
| Research License Liability |
|
|
240 |
|
|
|
Extended Research Period [Member]
|
|
|
|
|
|
| Research License Liability |
|
|
$ 380 |
|
|